Three-month treatment with pioglitazone reduces circulating levels of S100A8/A9 (MRP8/14) complex, a biomarker of inflammation, without changes in body mass index, in type 2 diabetics with abdominal obesity.

Abstract

We measured circulating S100A8/A9 (MRP8/14) complex levels before and after 3-month treatment with pioglitazone in type 2 diabetic patients. The results showed that pioglitazone reduced circulating S100A8/A9 complex levels, without changing body mass index, in type 2 diabetic patients with abdominal obesity.

• Authors: Hideaki Nakatsuji, Ken Kishida, Tohru Funahashi, Iichiro Shimomura, Senri Study II Group
• Journal: Diabetes research and clinical practice (Diabetes Res Clin Pract) Vol. 95 Issue 3 Pg. e58-60 (Mar 2012) ISSN: 1872-8227 [Electronic] Ireland
• PMID: 22154375 (Publication Type: Journal Article)
• Copyright: Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Chemical References

• Biomarkers
• Calgranulin A
• Calgranulin B
• Hypoglycemic Agents
• Thiazolidinediones
• Pioglitazone

Topics

• Aged
• Biomarkers (blood)
• Body Mass Index
• Calgranulin A (blood)
• Calgranulin B (blood)
• Diabetes Mellitus, Type 2 (drug therapy, pathology)
• Female
• Humans
• Hypoglycemic Agents
• Inflammation (drug therapy)
• Male
• Middle Aged
• Obesity, Abdominal
• Pioglitazone
• Thiazolidinediones (therapeutic use)